Mumbai, Quebec, August 23, 2024: Global pharma major Lupin Limited (Lupin) today announced that ithas received approval from Health Canada for its biosimilar Pegfilgrastim. This product will be marketed under the brand name Armlupeg® and manufactured at Lupin’s Biotech facility at Pune, India.

Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim. Pegfilgrastim prefilled syringesare indicated to decrease the incidence of infection, as manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.

Mr. Nilesh Gupta, Managing Director, Lupin said, “Weare committed to providing affordable and high-quality treatment to our patients. The Health Canada approval for Armlupeg® strengthens our ability to support Canadian patients with this mainstay treatment.”

Dr. Cyrus Karkaria, President, Biotech Division said, “Biosimilars play an important role providing access to cancer treatment and supportive care. We are happy to receive our second biosimilar approval in Canada and look forward to maintaining this momentum with additional launches in regulated markets.”

About Armlupeg® (pegfilgrastim)
Armlupeg® (pegfilgrastim) is a biosimilar comparable to the reference biologic drug NEULASTA® (pegfilgrastim). It is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.Armlupeg® is available in a form of pre-filled syringe of 6mg/0.6 ml.

About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin

For further information or queries please contact –

Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com

*Safe Harbor Statement
Neulasta® is a registered trademark of Amgen Inc.